December 2, 2025 08:46 AM EST
Updated 01:17 PM
StartupsR&D
Helicore stops work on clinical GIP antagonist after Phase 1 results, will focus on other drugs in pipeline
Kyle LaHucik
Biotech Correspondent
Helicore Biopharma has ended a clinical trial for its lead asset less than 12 months after emerging from stealth, and plans to shift focus to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS
Analyst – Life Sciences Strategy & Intelligence
Sedulo Group
Remote
VIEW JOB OFFER
post your job now